Bausch & Lomb vs ResMed|
Bausch & Lomb and ResMed| are similar in size: $5.10bn and $5.65bn of revenue in their latest fiscal years. ResMed| grew faster (9.9% against 6.5%). ResMed| kept more of each dollar of sales as profit: a net margin of 26.9% against -7.1%.
| Latest fiscal year | Bausch & LombBLCO, 2025 | ResMed|RMD, 2026 |
|---|---|---|
| Revenue | $5.10bn | $5.65bn |
| Revenue growth | 6.5% | 9.9% |
| Net income | −$360m | $1.52bn |
| Operating margin | 2.2% | — |
| Net margin | -7.1% | 26.9% |
| Return on equity | -5.6% | 24.3% |
| Free cash flow | −$66.0m | $1.65bn |
| Cash | $383m | $1.47bn |
| Total debt | $5.11bn | $659m |
| Debt to equity | 79.2% | — |
| Dividend per share | — | $2.40 |
| Dividend yield | — | 1.1% |
| Share buybacks | — | $700m |
| Employees | — | 11,370 |
| Market value | $7.14bn | $31.58bn |
| Price vs our value range | — | Within our value range |
| Moat score | 19 (Weak) | 88 (Strong) |
| Insider trades, 12 months | 9 buys, 4 sales | 0 buys, 32 sales |